Derek Streat

Derek is Founder, CEO and Chairman of DexCare. He is an accomplished healthcare technology entrepreneur and executive, having co-founded and/or been at the earliest stages of six venture-backed companies including C-SATS (acquired by Johnson & Johnson), Classmates (acquired by United Online), Medify (acquired by Alliance Health Networks) and AdReady (acquired by CPXi).

Prior to joining Providence as an Entrepreneur-in-Residence to commercialize the DexCare platform, Derek served as VP of Digital Solutions at Johnson & Johnson - a role he assumed after C-SATS was acquired by the world’s largest healthcare company. There he led the charge to transform the organization responsible for training 250,000 surgeons worldwide into a leading healthcare quality improvement and continuous learning institution that directly advanced patient outcomes, provider efficiency, and health system value through digital solutions.

Derek is also actively involved in national healthcare data transparency efforts for the improvement of patient care as a Co-Founder and Board member of two leading data sharing organizations, PEDSnet and the Improving Renal Outcomes Collaborative (IROC).

Posts by Derek Streat

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

Consumer / Employer

23andMe: What If …

A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision?

presented by
Daily, Hospitals, Providers

Hospital M&A Activity in 2024: What to Expect

Q1 2024 saw a significant rise in the number of hospital M&A deals compared to the past three Q1s. Experts believe this M&A activity will continue to climb throughout this year and next — motivated by both financial distress and hospitals’ desire to improve strategic business lines like value-based care and digital healthcare services.